Metraipolis › archive › dc_77f544f64bd5

Comparative Cardiovascular Outcomes in Acalabrutinib vs. Zanubrutinib in B-Cell Malignancies: A TriNetX Data Study — Europe PMC PMID:42930208

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42930208
DOI
10.3390/curroncol33100641
License (as archived)
solo-consultazione
Archived
2026-10-31T09:17:43.609Z
SHA-256 of the archived text
0508cde0cb3a1e7ddd37f1d023b472ca735a959ff95e78cf1e7d85008abdd327
Stable URL of this page
https://metraipolis.com/documento/dc_77f544f64bd5

How to cite

Comparative Cardiovascular Outcomes in Acalabrutinib vs. Zanubrutinib in B-Cell Malignancies: A TriNetX Data Study — Europe PMC PMID:42930208 — Europe PMC (en), https://europepmc.org/article/MED/42930208 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_77f544f64bd5 (Metraipolis archive dc_77f544f64bd5, sha256 0508cde0cb3a1e7ddd37f1d023b472ca735a959ff95e78cf1e7d85008abdd327)
BibTeX
@misc{dc77f544f64bd5,
  title = {Comparative Cardiovascular Outcomes in Acalabrutinib vs. Zanubrutinib in B-Cell Malignancies: A TriNetX Data Study — Europe PMC PMID:42930208},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42930208},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_77f544f64bd5; sha256 0508cde0cb3a1e7ddd37f1d023b472ca735a959ff95e78cf1e7d85008abdd327},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42930208. Agents can read the archived copy with the MCP tool read_document.